NY-ESO-1 Knockout A375 Cell Line

NY-ESO-1 Knockout A375 Cell Line is an A375 human melanoma cell line in which NY-ESO-1 (New York esophageal squamous cell carcinoma 1, also known as Cancer/Testis Antigen 1 or CTAG1B) is no longer expressed due to CRISPR/Cas9 genome editing. This cell line was generated by electroporation of A375 cells with ribonucleoprotein complexes of Cas9 and sgRNAs targeting CTAG1B. This cell line has been validated by genomic sequencing, western blot, and in a co-culture assay. These cells do not activate T-cells expressing a TCR (T cell receptor) that specifically recognizes NY-ESO-1. NY-ESO-1 (New York esophageal squamous cell carcinoma 1, also known as Cancer/testis antigen 1, or CTAG1B), is an important tumorigenic marker present in malignant cells. Normally expressed only in embryonic testis, this highly immunogenic protein is not usually found in normal tissues, but can be re-expressed in cancers including melanoma, multiple myeloma (MM), non-small cell lung carcinoma (NSCLC), and breast and ovarian cancer, making it a promising candidate antigen for cancer immunotherapy. Several NY-ESO-1-directed therapies are being developed including cancer vaccines, anti-NY-ESO-1 adoptive cell therapy, and NY-ESO-1-specific TCR (T-cell receptor)-T cell therapy in combination with checkpoint inhibitors.